For patients with high-risk DLBCL who often fail R-CHOP therapy, especially patients with high-grade B-cell lymphoma with MYC and BCL2 or BCL6 translocation, dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA.R-EPOCH) regimen is a commonly used high intensity regimen. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.